Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 240 mg - capsule, modified release - excipient ingredients: ethylcellulose; simethicone; purified talc; castor oil; tributyl acetylcitrate; white beeswax; methacrylic acid copolymer; titanium dioxide; gelatin; colloidal anhydrous silica; brilliant blue fcf; stearic acid; fumaric acid; maize starch; sucrose - diltiazem sandoz cd is indicated for the treatment of hypertension. diltiazem sandoz cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 180 mg - capsule, modified release - excipient ingredients: fumaric acid; gelatin; methacrylic acid copolymer; brilliant blue fcf; white beeswax; stearic acid; colloidal anhydrous silica; simethicone; ethylcellulose; titanium dioxide; tributyl acetylcitrate; castor oil; purified talc; maize starch; sucrose - diltiazem sandoz cd is indicated for the treatment of hypertension. diltiazem sandoz cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 360 mg - capsule, modified release - excipient ingredients: methacrylic acid copolymer; diethyl phthalate; sodium lauryl sulfate; purified talc; povidone; simethicone; tributyl acetylcitrate; maize starch; sucrose; titanium dioxide; brilliant blue fcf; potable water; gelatin; silicon dioxide - vasocardol cd is indicated for the treatment of hypertension. vasocardol cd is also indicated for the management of chronic stable angina (effort associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 360 mg - capsule, modified release - excipient ingredients: purified talc; methacrylic acid copolymer; povidone; tributyl acetylcitrate; sodium lauryl sulfate; diethyl phthalate; simethicone; maize starch; sucrose; titanium dioxide; brilliant blue fcf; potable water; gelatin; silicon dioxide - cardizem cd is indicated for the treatment of hypertension. cardizem cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 240 mg - capsule, modified release - excipient ingredients: gelatin; brilliant blue fcf; ethylcellulose; titanium dioxide; tributyl acetylcitrate; castor oil; methacrylic acid copolymer; stearic acid; purified talc; fumaric acid; simethicone; white beeswax; colloidal anhydrous silica; maize starch; sucrose - vasocardol cd is indicated for the treatment of hypertension. vasocardol cd is also indicated for the management of chronic stable angina (effort associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 180 mg - capsule, modified release - excipient ingredients: purified talc; fumaric acid; gelatin; methacrylic acid copolymer; stearic acid; simethicone; white beeswax; castor oil; ethylcellulose; tributyl acetylcitrate; brilliant blue fcf; titanium dioxide; colloidal anhydrous silica; maize starch; sucrose - vasocardol cd is indicated for the treatment of hypertension. vasocardol cd is also indicated for the management of chronic stable angina (effort associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 240 mg - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; methacrylic acid copolymer; colloidal anhydrous silica; titanium dioxide; white beeswax; tributyl acetylcitrate; castor oil; stearic acid; purified talc; simethicone; brilliant blue fcf; fumaric acid; maize starch; sucrose - cardizem cd is indicated for the treatment of hypertension. cardizem cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 180 mg - capsule, modified release - excipient ingredients: colloidal anhydrous silica; methacrylic acid copolymer; titanium dioxide; stearic acid; fumaric acid; tributyl acetylcitrate; castor oil; simethicone; ethylcellulose; purified talc; brilliant blue fcf; gelatin; white beeswax; maize starch; sucrose - cardizem cd is indicated for the treatment of hypertension. cardizem cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended.

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen-cilag ltd - itraconazole - capsule, hard - 100 milligram(s) - triazole derivatives; itraconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

merus labs luxco ii s.à.r.l. - isosorbide mononitrate - prolonged-release capsule, hard - 25 milligram(s) - organic nitrates; isosorbide mononitrate